Follow
LAG3 ICIs
"With this approval, LAG-3 became the third checkpoint inhibitor to show efficacy when targeted in the clinic, The response profile of Opdualag is comparable to the ipilimumab/nivolumab (anti-CTLA4/anti-PD-1) combination (47.7% versus 49% 12-month PFS), although 59% of patients had severe adverse events with ipilimumab/nivolumab compared with only 18.9% with Opdualag"
